Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors
作者:Chen Wang、Jinyun Dong、Yanmin Zhang、Fang Wang、Hongping Gao、Pengfei Li、Sicen Wang、Jie Zhang
DOI:10.1039/c3md00192j
日期:——
VEGFR-2 plays a critical role in vasculogenesis and VEGFR-2 inhibitors have been widely used in the treatment of cancer. In our continued efforts to search for potent and novel VEGFR-2 inhibitors as antitumor agents, we have identified a potent lead compound (HMQ-16) bearing a biphenyl scaffold. Rearrangement and replacement of arylcarbamoyl in HMQ-16 with a urea moiety generated a series of novel VEGFR-2 inhibitors. In order to enhance the affinity with VEGFR-2, the 4′-acetyl group was converted to an oxime group. Fourteen biphenyl urea derivatives were designed and synthesized as potent VEGFR-2 inhibitors. Six of them (T2, T5, T7, T9, T11, T14) exhibited potent VEGFR-2 inhibitory activity comparable to that of sorafenib. Compound T7 was the most potent with an IC50 value of 1.08 nM. The enzymatic and cellular assays suggested that T7 has potential as a valuable lead compound for further optimization.
VEGFR-2 在血管生成过程中起着关键作用,VEGFR-2 抑制剂已被广泛用于治疗癌症。我们一直在努力寻找强效的新型 VEGFR-2 抑制剂作为抗肿瘤药物,在此过程中,我们发现了一种具有联苯支架的强效先导化合物(HMQ-16)。将 HMQ-16 中的芳基氨基甲酰基重新排列并替换为脲基,产生了一系列新型 VEGFR-2 抑制剂。为了增强与 VEGFR-2 的亲和力,4′-乙酰基被转化为肟基。研究人员设计并合成了 14 种联苯脲衍生物,作为有效的 VEGFR-2 抑制剂。其中六种(T2、T5、T7、T9、T11、T14)表现出与索拉非尼相当的强效 VEGFR-2 抑制活性。化合物 T7 的 IC50 值为 1.08 nM,效力最强。酶和细胞检测结果表明,T7 有可能成为一种有价值的先导化合物,有待进一步优化。